ATRO.NASDAQAstronics CORP

Form 4: Astronics Corp Executive James Mulato Reports Stock Transactions

Sentiment:

SEC Form 4 Filing

📋All filings for Astronics CORP
🔒Login to Follow

James Mulato, an executive at Astronics Corp, reports acquiring shares through an employee stock purchase plan and adjustments to his holdings of common stock, Class B stock, and derivative securities.

Summary

  • On September 30, 2024, James Mulato, President of Astronics Test Systems, reported transactions involving Astronics Corp stock.
  • Mulato acquired 1,574 shares of common stock at $13.50 per share through the Employee Stock Purchase Plan.
  • He also disposed of 1,195 shares of Class B stock.
  • Following these transactions, Mulato directly owns 36,166.822 shares of common stock.
  • Additionally, he indirectly owns 100 shares of common stock and 32 shares of Class B stock through his spouse.
  • Mulato also holds various options to purchase common stock and Class B stock at prices ranging from $9.74 to $35.61, with expiration dates between 2024 and 2033.
  • He also holds restricted stock units (RSUs) that will vest based on Astronics Corp's average annual adjusted EBITDA performance over different periods.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document primarily reports transactions and holdings. The acquisition of shares through the employee stock purchase plan is a slightly positive signal, while the disposal of Class B stock is a slightly negative signal. The vesting of RSUs based on EBITDA performance introduces a degree of uncertainty.

Positives

  • The acquisition of shares through the Employee Stock Purchase Plan indicates Mulato's confidence in the company's future.

Negatives

  • The disposal of 1,195 shares of Class B stock could be interpreted negatively, although the reason for the disposal is not specified.

Risks

  • The vesting of restricted stock units is contingent on the company's average annual adjusted EBITDA performance, which introduces uncertainty.

Future Outlook

The vesting of restricted stock units is tied to the company's future EBITDA performance, suggesting a focus on achieving specific financial targets.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. Monitoring these filings can offer insights into management's sentiment and expectations regarding the company's performance.

Comparison to Industry Standards

  • Comparing Astronics Corp's executive compensation structure, including stock options and RSUs, to that of peers like HEICO Corporation or TransDigm Group can provide insights into whether the incentives are aligned with industry norms.
  • The vesting conditions tied to EBITDA performance are a common practice, similar to those used by companies like Teledyne Technologies or Curtiss-Wright Corporation, to incentivize management to achieve specific financial goals.

Stakeholder Impact

  • Shareholders may be interested in the insider's transactions as an indicator of management's confidence in the company.
  • Employees participating in the Employee Stock Purchase Plan are directly affected by the reported transactions.
  • The vesting of restricted stock units based on EBITDA performance can impact employee morale and motivation.

Key Dates

DateDescription
12/11/2015Date of options grant with exercise price $30.83 and expiration date 12/11/2024
12/03/2016Date of options grant with exercise price $27.72 and expiration date 12/03/2025
12/14/2017Date of options grant with exercise price $31.76 and expiration date 12/14/2026
12/12/2018Date of options grant with exercise price $35.61 and expiration date 12/12/2027
12/13/2019Date of options grant with exercise price $31.57 and expiration date 12/13/2028
12/09/2020Date of options grant with exercise price $30.04 and expiration date 12/09/2029
01/22/2022Date of options grant with exercise price $14.45 and expiration date 01/22/2031
01/01/2022Start date for EBITDA performance period for restricted stock units vesting on February 24, 2025.
12/09/2022Date of options grant with exercise price $11.13 and expiration date 12/09/2031
01/01/2023Start date for EBITDA performance period for restricted stock units vesting on February 23, 2026.
12/16/2023Date of options grant with exercise price $9.74 and expiration date 12/16/2032
01/01/2024Start date for EBITDA performance period for restricted stock units vesting on February 22, 2027.
12/07/2024Date of options grant with exercise price $15.15 and expiration date 12/07/2033
09/30/2024Date of the reported stock transactions.
10/02/2024Date of signature for the report.
12/11/2024Expiration date for options granted on 12/11/2015.
02/24/2025Potential vesting date for restricted stock units based on EBITDA performance from January 1, 2022 to December 31, 2024.
12/03/2025Expiration date for options granted on 12/03/2016.
02/23/2026Potential vesting date for restricted stock units based on EBITDA performance from January 1, 2023 to December 31, 2025.
12/14/2026Expiration date for options granted on 12/14/2017.
02/22/2027Potential vesting date for restricted stock units based on EBITDA performance from January 1, 2024 to December 31, 2026.
12/12/2027Expiration date for options granted on 12/12/2018.
12/13/2028Expiration date for options granted on 12/13/2019.
12/09/2029Expiration date for options granted on 12/09/2020.
01/22/2031Expiration date for options granted on 01/22/2022.
12/09/2031Expiration date for options granted on 12/09/2022.
12/16/2032Expiration date for options granted on 12/16/2023.
12/07/2033Expiration date for options granted on 12/07/2024.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.